Zhongheng Group: Wholly-owned subsidiary Zhongheng Innovation acquires a drug technology for treating chronic heart failure for 55 million yuan
Zhongheng Group announced that its wholly-owned subsidiary Zhongheng Innovation has acquired a technology for treating chronic heart failure from China Rongtong Scientific Research Institute Group Co., Ltd. through a transfer method, with a transaction price of RMB 55 million. This transaction does not constitute a related party transaction and does not constitute a major asset reorganization. This transaction has been approved by the 29th meeting of the 10th Board of Directors of the company and does not require submission for shareholder meeting approval
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments